Biotech Values

[DewDiligence]

BMY inks AD target-discovery deal with Gladstone Institutes:

http://finance.yahoo.com/news/Bristol-Myers-Squibb-bw-3666145478.html?x=0

Under the agreement, Bristol-Myers Squibb will fund Gladstone’s research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell’s internal skeleton and may help regulate the activity of brain cells. In Alzheimer’s disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.

Financial terms are not disclosed. Gladstone is a non-profit affiliated with UCSF.